Patrick Lu
About Patrick Lu
Patrick Lu is the President and CEO of Sirnaomics, Inc., a company he founded in 2007. With over 25 years of experience in nucleic acid drug development, he has led significant projects including the development of the siRNA therapeutic STP705.
Work at Sirnaomics
Patrick Lu has served as the President and CEO of Sirnaomics, Inc. since its founding in 2007. Under his leadership, the company has focused on the development of nucleic acid therapeutics. He also holds the position of Chairman of the Board of Directors. His tenure at Sirnaomics has been marked by significant fundraising efforts, successfully raising over $270 million to support the company's clinical programs. The company operates out of Gaithersburg, Maryland, and aims to advance innovative treatments for various diseases.
Education and Expertise
Patrick Lu has an extensive educational background in the biological sciences. He earned a Bachelor of Science in Botany, a Master of Science in Population Biology, and a Ph.D. in Biostatistics from Sun Yat-sen University, completing his studies between 1978 and 1987. He furthered his education at the University of Maryland at College Park, where he completed a Post Doctoral Fellowship in Molecular Plant Pathology from 1987 to 1990. Additionally, he studied Molecular Cancer Pharmacology at Georgetown University School of Medicine, achieving the status of Research Fellow from 1990 to 1992.
Background
Patrick Lu has over 25 years of experience in nucleic acid drug development. His career includes significant roles at notable companies such as Novartis and Digene. Prior to founding Sirnaomics, he co-founded Intradigm, a company focused on nucleic acid therapeutics. His extensive background in the field has equipped him with the knowledge and skills necessary to lead innovative research and development initiatives in drug development.
Achievements
During his career, Patrick Lu has been instrumental in the development of STP705, a novel siRNA therapeutic designed to target cancer and fibrosis diseases. His efforts in fundraising have also been notable, having successfully raised $58 million specifically for advancing clinical programs at Sirnaomics. His contributions to the field of nucleic acid drug development reflect his commitment to advancing therapeutic options for patients.